Skip to content

Released Mar 7, 2025, after the close

10-K filed Mar 7, 2025, 66 days after period end · 0001410578-25-000300

Q4 2024 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$4.03Mderivedno prior Q4 2023 on file+58.4% vs Q3 2024
Net Income-$4.95Mderivedno prior Q4 2023 on fileN/M vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$2,962,000—
Operating Incomederived-$8,345,000—
Operating Cash Flowderived-$5,879,000—
Margins · derived
Gross margin73.6%
Operating margin-207.3%
Net margin-122.9%

What the release said

The release

Same quarter

no prior Q4 2023 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Profound Medical Corp. · CIK 1628808 · Engraved from SEC EDGAR